|
1
|
Kleeff J, Michalski C, Friess H and
Büchler MW: Pancreatic cancer: From bench to 5-year survival.
Pancreas. 33:111–118. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kwon HJ and Kim SG: Surgical treatment for
advanced pancreatic cancer. Korean J Hepatobiliary Pancreat Surg.
16:89–92. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lowenfels AB and Maisonneuve P:
Epidemiology and risk factors for pancreatic cancer. Best Pract Res
Clin Gastroenterol. 20:197–209. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yeo CJ, Cameron JL, Lillemoe KD, Sitzmann
JV, Hruban RH, Goodman SN, Dooley WC, Coleman J and Pitt HA:
Pancreaticoduodenectomy for cancer of the head of the pancreas. 201
patients. Ann Surg. 221:721–733. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Eto S, Ishikawa M, Asanoma M, Tashiro Y,
Matsuyama K and Oshio T: A long-term survival case of advanced
biliary cancer with repeated resection due to recurrence in the
pancreaticogastrostomy site after pancreaticoduodenectomy. Ann
Hepatobiliary Pancreat Surg. 22:173–177. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kim HS, Jang JY, Han Y, Lee KB, Joo I, Lee
DH, Kim JR, Kim H, Kwon W and Kim SW: Survival outcome and
prognostic factors of neoadjuvant treatment followed by resection
for borderline resectable pancreatic cancer. Ann Surg Treat Res.
93:186–194. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Arnedos M, Vicier C, Loi S, Lefebvre C,
Michiels S, Bonnefoi H and Andre F: Precision medicine for
metastatic breast cancer-limitations and solutions. Nat Rev Clin
Oncol. 12:693–704. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Friedman AA, Letai A, Fisher DE and
Flaherty KT: Precision medicine for cancer with next-generation
functional diagnostics. Nat Rev Cancer. 15:747–756. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Selkoe D and Kopan R: Notch and
presenilin: Regulated intramembrane proteolysis links development
and degeneration. Annu Rev Neurosci. 26:565–597. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhao G, Liu Z, Ilagan MX and Kopan R:
Gamma-secretase composed of PS1/Pen2/Aph1a can cleave notch and
amyloid precursor protein in the absence of nicastrin. J Neurosci.
30:1648–1656. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
De Strooper B: Aph-1, Pen-2, and Nicastrin
with Presenilin generate an active gamma-Secretase complex. Neuron.
38:9–12. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ran Y, Hossain F, Pannuti A, Lessard CB,
Ladd GZ, Jung JI, Minter LM, Osborne BA, Miele L and Golde TE:
γ-Secretase inhibitors in cancer clinical trials are
pharmacologically and functionally distinct. EMBO Mol Med.
9:950–966. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Halawany AME, Sayed NSE, Abdallah HM and
Dine RSE: Protective effects of gingerol on streptozotocin-induced
sporadic Alzheimer's disease: Emphasis on inhibition of β-amyloid,
COX-2, alpha-, beta-secretases and APH1a. Sci Rep. 7:29022017.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Penton AL, Leonard LD and Spinner NB:
Notch signaling in human development and disease. Semin Cell Dev
Biol. 23:450–457. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
International Cancer Genome Consortium, ;
Hudson TJ, Anderson W, Artez A, Barker AD, Bell C, Bernabé RR, Bhan
MK, Calvo F, Eerola I, et al: International network of cancer
genome projects. Nature. 464:993–998. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shih IeM and Wang TL: Notch signaling,
gamma-secretase inhibitors, and cancer therapy. Cancer Res.
67:1879–1882. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Takebe N, Nguyen D and Yang SX: Targeting
notch signaling pathway in cancer: Clinical development advances
and challenges. Pharmacol Ther. 141:140–149. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yuan X, Wu H, Xu H, Xiong H, Chu Q, Yu S,
Wu GS and Wu K: Notch signaling: An emerging therapeutic target for
cancer treatment. Cancer Lett. 369:20–27. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mizuma M, Rasheed ZA, Yabuuchi S, Omura N,
Campbell NR, de Wilde RF, De Oliveira E, Zhang Q, Puig O, Matsui W,
et al: The gamma secretase inhibitor MRK-003 attenuates pancreatic
cancer growth in preclinical models. Mol Cancer Ther. 11:1999–2009.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
So JY, Wahler J, Das Gupta S, Salerno DM,
Maehr H, Uskokovic M and Suh N: HES1-mediated inhibition of Notch1
signaling by a Gemini vitamin D analog leads to decreased
CD44(+)/CD24(−/low) tumor-initiating subpopulation in basal-like
breast cancer. J Steroid Biochem Mol Biol. 148:111–121. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cancer Genome Atlas Research Network, ;
Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA,
Ellrott K, Shmulevich I, Sander C and Stuart JM: The cancer genome
atlas pan-cancer analysis project. Nat Genet. 45:1113–1120. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cerami E, Gao J, Dogrusoz U, Gross BE,
Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et
al: The cBio cancer genomics portal: An open platform for exploring
multidimensional cancer genomics data. Cancer Discov. 2:401–404.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Stratford JK, Bentrem DJ, Anderson JM, Fan
C, Volmar KA, Marron JS, Routh ED, Caskey LS, Samuel JC, Der CJ, et
al: A six-gene signature predicts survival of patients with
localized pancreatic ductal adenocarcinoma. PLoS Med.
7:e10003072010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Badea L, Herlea V, Dima SO, Dumitrascu T
and Popescu I: Combined gene expression analysis of whole-tissue
and microdissected pancreatic ductal adenocarcinoma identifies
genes specifically overexpressed in tumor epithelia.
Hepatogastroenterology. 55:2016–2027. 2008.PubMed/NCBI
|
|
25
|
Pei H, Li L, Fridley BL, Jenkins GD,
Kalari KR, Lingle W, Petersen G, Lou Z and Wang L: FKBP51 affects
cancer cell response to chemotherapy by negatively regulating Akt.
Cancer Cell. 16:259–266. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang G, He P, Tan H, Budhu A, Gaedcke J,
Ghadimi BM, Ried T, Yfantis HG, Lee DH, Maitra A, et al:
Integration of metabolomics and transcriptomics revealed a fatty
acid network exerting growth inhibitory effects in human pancreatic
cancer. Clin Cancer Res. 19:4983–4993. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Amin MB, Greene FL, Edge SB, Compton CC,
Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR and
Winchester DP: The Eighth Edition AJCC Cancer Staging Manual:
Continuing to build a bridge from a population-based to a more
‘personalized’ approach to cancer staging. CA Cancer J Clin.
67:93–99. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cho SH, Pak K, Jeong DC, Han ME, Oh SO and
Kim YH: The AP2M1 gene expression is a promising biomarker for
predicting survival of patients with hepatocellular carcinoma. J
Cell Biochem. 120:4140–4146. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ha M, Kim JY, Han ME, Kim GH, Park SY,
Jeong DC, Oh SO and Kim YH: TMEM18: A novel prognostic marker in
acute myeloid leukemia. Acta Haematol. 140:71–76. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Han ME, Kim JY, Kim GH, Park SY, Kim YH
and Oh SO: SAC3D1: A novel prognostic marker in hepatocellular
carcinoma. Sci Rep. 8:156082018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Goh TS, Lee JS, Il Kim J, Park YG, Pak K,
Jeong DC, Oh SO and Kim YH: Prognostic scoring system for
osteosarcoma using network-regularized high-dimensional
Cox-regression analysis and potential therapeutic targets. J Cell
Physiol. Jan 3–2019.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ha M, Han ME, Kim JY, Jeong DC, Oh SO and
Kim YH: Prognostic role of TPD52 in acute myeloid leukemia: A
retrospective multicohort analysis. J Cell Biochem. 120:3672–3678.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Fong ZV and Winter JM: Biomarkers in
pancreatic cancer: Diagnostic, prognostic, and predictive. Cancer
J. 18:530–538. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Winter JM, Yeo CJ and Brody JR:
Diagnostic, prognostic, and predictive biomarkers in pancreatic
cancer. J Surg Oncol. 107:15–22. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chen Y, De Marco MA, Graziani I, Gazdar
AF, Strack PR, Miele L and Bocchetta M: Oxygen concentration
determines the biological effects of NOTCH-1 signaling in
adenocarcinoma of the lung. Cancer Res. 67:7954–7959. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Al-Hussaini H, Subramanyam D, Reedijk M
and Sridhar SS: Notch signaling pathway as a therapeutic target in
breast cancer. Mol Cancer Ther. 10:9–15. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Han J and Shen Q: Targeting γ-secretase in
breast cancer. Breast Cancer (Dove Med Press). 4:83–90.
2012.PubMed/NCBI
|
|
38
|
Harrison H, Farnie G, Brennan KR and
Clarke RB: Breast cancer stem cells: Something out of notching?
Cancer Res. 70:8973–8976. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kondratyev M, Kreso A, Hallett RM,
Girgis-Gabardo A, Barcelon ME, Ilieva D, Ware C, Majumder PK and
Hassell JA: Gamma-secretase inhibitors target tumor-initiating
cells in a mouse model of ERBB2 breast cancer. Oncogene. 31:93–103.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Peltonen HM, Haapasalo A, Hiltunen M,
Kataja V, Kosma VM and Mannermaa A: Γ-secretase components as
predictors of breast cancer outcome. PLoS One. 8:e792492013.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Placanica L, Tarassishin L, Yang G,
Peethumnongsin E, Kim SH, Zheng H, Sisodia SS and Li YM: Pen2 and
presenilin-1 modulate the dynamic equilibrium of presenilin-1 and
presenilin-2 gamma-secretase complexes. J Biol Chem. 284:2967–2977.
2009. View Article : Google Scholar : PubMed/NCBI
|
